+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae



Risk Factors for Ciprofloxacin Resistance in Bloodstream Infections Due to Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae



Microbial Drug Resistance 10(1): 71-76



The present study was conducted to identify risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta -lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK). ESBL production was determined in stored E. coli and K. pneumoniae blood isolates from January, 1998, to December, 2002, by National Committee for Clinical Laboratory Standards (NCCLS) guidelines and/or double-disk synergy test. Antimicrobial susceptibility was determined by the disk diffusion test method. A total of 133 patients with ESBL-EK bacteremia were analyzed retrospectively. A total of 80 (60.2%) patients experienced bacteremia due to strains resistant to ciprofloxacin. There were no significant differences in age, sex, and APACHE II score between the ciprofloxacin-resistant group (CIP-R) and-susceptible group (CIPS). The most common primary site of infection in CIP-R was pancreaticobiliary tract infection (46/80, 57.5%) and that in CIP-S was unknown primary site (23/53, 43.4%). Independent risk factors for ciprofloxacin resistance were: prior use of fluoroquinolones (OR, 5.53; 95% CI, 1.56-25.42, p = 0.032), indwelling urinary catheter (OR, 3.68; 95% CI, 1.27-10.67, p = 0.017), and invasive procedure within 72 hr prior to bacteremia (OR, 4.03; 95% CI, 1.44-11.25, p = 0.008). Our data suggest that strategies designed to reduce the ciprofloxacin resistance rate in ESBL-EK strains should focus on limiting the use of fluoroquinolones and minimizing invasive procedures, including insertion of a urinary catheter.

(PDF emailed within 0-6 h: $19.90)

Accession: 060210463

Download citation: RISBibTeXText

PMID: 15140397

DOI: 10.1089/107662904323047835


Related references

Risk factors for ciprofloxacin resistance in bloodstream infections due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 365, 2003

Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Revista do Instituto de Medicina Tropical de Sao Paulo 51(4): 211-216, 2009

Risk factors for bloodstream infections caused by extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae. The Brazilian Journal of Infectious Diseases 15(4): 370-376, 2011

Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Brazilian Journal of Infectious Diseases 15(4): 370-376, 2012

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrobial Agents and ChemoTherapy 48(12): 4574-4581, 2004

Bloodstream infections due to extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae Risk factors for mortality and clinical outcome, with special emphasis on antimicrobial therapy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 364, 2003

Risk factors for the emergence of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase -producing Escherichia coli and Klebsiella pneumoniae. Clinical Infectious Diseases 31(1): 212, 2000

Risk factors and prognosis in 31 patients with extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bloodstream infection. Zhonghua Jie He He Hu Xi Za Zhi 31(11): 815-819, 2010

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Medicine 28(12): 1718-1723, 2002

Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Journal of Microbiology, Immunology, and Infection 50(3): 355-361, 2015

Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infection Control and Hospital Epidemiology 29(7): 671-674, 2008

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrobial Agents and ChemoTherapy 46(5): 1481-1491, 2002

Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Journal of the Association of Physicians of India 58 Suppl: 41-44, 2011

Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clinical Infectious Diseases 32(8): 1162-1171, 2001

Impact of a clonal outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K pneumoniae and Escherichia coli an 11 year experience in Oxfordshire, UK. 2011